About Us > Management Team
Dr Jason Slingsby, MBA
Chief Executive Officer
Jason is co-founder and CEO of ProtAffin AG since 2005. He has worked over the last 14 years at the listed biotech companies Oxford BioMedica (UK), Sosei Co. Ltd (UK/Japan) and Intercell (Austria). He was awarded a 1st class honours degree in Biochemistry at Magdalen College, Oxford University, and was awarded a PhD in Inflammatory Disease Genetics by Imperial College London under supervisor Prof. Mark Walport, the current Chief Executive of the Wellcome Trust. He was later awarded an MBA with Distinction from London Business School, where he focussed on innovative technology companies and general management. Jason has published a number of scientific papers and is inventor on a number of patents.
Prof. Andreas Kungl
Chief Scientific Officer
Andreas is co-founder and CSO of ProtAffin. He is Professor at the University of Graz and, before joining ProtAffin, he worked at the Max Planck Biochemistry Institute in Martinsried, Germany, and at the Novartis Research Institute in Vienna for five years. Andreas has coordinated a number of national and European projects in the field of chemokine therapeutic strategies, protein-glycan interactions and glycomics. Andreas is a recognised authority in the basis of protein-glycan interactions.
Dr Mike Bartley
Chief Development Officer
Mike is Chief Development Officer of ProtAffin AG since 2011. He has worked for the last 10 years for Pfizer Inc, most recently leading early clinical- stage projects in respiratory diseases, taking several anti-inflammatory candidates from novel mechanistic classes into the clinic. Mike studied at Imperial College London and Queen Mary College London, before joining ICI (Zeneca, Syngenta) agrochemicals, where he led projects in many R&D areas, several to project launch. Mike has published a number of scientific papers and is inventor on a number of patents.